EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study

Kyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, Taro Shibuki, Chigusa Morizane, Norio Nonomura, Hiroji Iwata, Hidemichi Watari, Susumu Okano, Kenjiro Namikawa, Yoichi Naito, Hideaki Bando und 1 weitere

International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1431-1440

DOI: 10.1007/s10147-026-03069-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 06.06.2026. Verfasst von Kyosuke Seguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japa…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Certification, Oncologists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with treatment quality and survival.

Methods

This retrospective cohort study used data from the SCRUM-Japan MONSTAR-SCREEN observational study, a nationwide multicenter genomic screening program enrolling patients from 2019 to 2022. Standard treatment implementation rates were compared across cancer types as a secondary outcome. The primary outcome was overall survival (OS) in patients with metastatic colorectal cancer (mCRC) using Kaplan–Meier analysis and Cox proportional hazards regression with sequential adjustment for clinical and molecular covariates.

Results

Among 2,184 patients, standard treatment rates were comparable between board-certified and non–board-certified groups (97.0% vs. 96.9%). In 358 patients with mCRC, enrollment by a board-certified physician was associated with longer OS (median, 36.5 vs. 30.7 months; hazard ratio (HR): 0.66, 95% CI 0.50–0.87; log-rank p = 0.003) even after adjustment for age, sex, tumor sidedness, region, trial participation, molecular targeted therapy, metastatic organ count (HR, 0.73; 95% CI 0.55–0.97; p = 0.029), and after additional adjustment for RAS and BRAF V600E status (HR, 0.64; 95% CI 0.47–0.88; p = 0.005). Board-certified physicians used molecular targeted therapy more frequently (89.5% vs. 80.4%; p = 0.036).

Conclusions

JSMO board certification was independently associated with improved OS in mCRC despite comparable guideline adherence, suggesting that specialist expertise extends beyond treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCertificationOncologistsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedJapanNeoplasm Metastasis

Stichwörter der Autor:innen

Board certificationChemotherapyColorectal cancerGuideline adherenceMedical oncologistTargeted therapy

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Zitieren

APA

Seguchi, K., Hashimoto, T., Fujisawa, T., Shibuki, T., Morizane, C., Nonomura, N., Iwata, H., Watari, H., Okano, S., Namikawa, K., Naito, Y., Bando, H., & Yoshino, T. (2026). Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study. International Journal of Clinical Oncology, 31(8), 1431-1440. https://doi.org/10.1007/s10147-026-03069-0

Vancouver

Seguchi K, Hashimoto T, Fujisawa T, Shibuki T, Morizane C, Nonomura N, et al. Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study. International Journal of Clinical Oncology. 2026;31(8):1431-1440. doi:10.1007/s10147-026-03069-0

BibTeX
@article{Seguchi2026,
  author = {Seguchi, Kyosuke and Hashimoto, Tadayoshi and Fujisawa, Takao and Shibuki, Taro and Morizane, Chigusa and Nonomura, Norio and Iwata, Hiroji and Watari, Hidemichi and Okano, Susumu and Namikawa, Kenjiro and Naito, Yoichi and Bando, Hideaki and Yoshino, Takayuki},
  title = {Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {8},
  pages = {1431--1440},
  doi = {10.1007/s10147-026-03069-0}
}
Kostenlos starten →